Innovative immunotherapeutic strategies show promise against difficult-to-treat cancers. Researchers engineered macrophages to target melanoma more precisely, advancing cell-based cancer treatments by harnessing innate immune responses. Separately, scientists at UC Irvine developed glycan-dependent T cell recruiter (GlyTR) drugs that selectively bind tumor-associated carbohydrate antigens, achieving potent pan-cancer immunotherapy with minimized toxicity to healthy tissue.